Company Analysis

Sana Biotechnology, Inc. (SANA)

Nasdaq: SANA · Biological Products, (No Diagnostic Substances) · Seattle, WA · filing with the SEC since 2020
Grade5.0
◀ Past 6.2● Present 4.6▶ Future 4.5
6 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Report filedMar 3, 2026Mar 17, 2025Feb 29, 2024Mar 16, 2023Mar 16, 2022Mar 24, 2021·
Research and development131,980215,673r261,809r285,885248,626132,94499,591
General and administrative44,29664,04073,29971,56150,41028,27021,777
Total operating expenses250,319272,723293,141272,564356,909286,149141,152
Operating income-250,319-272,723-293,141-272,564-356,909-286,149-141,152
Interest income (expense), net3,84810,4719,9383,7626767472,856
Other income (expense), net2,305-4,507-52-67430597-29
Income before income taxes····-355,928-285,305-138,325
Income tax expense0·····-7,547
Net income including non-controlling interests-244,166-266,759-283,255-269,476-355,928-285,305-130,778
Net income-244,166-266,759-283,255-269,476-355,928-285,305-130,778
Earnings per share, basic-0.96-1.16-1.46-1.43-2.14-21.92·
Earnings per share, diluted-0.96-1.16-1.46-1.43-2.14-21.92·
Earnings per share, basic and diluted····-2.14-21.92-26.68
Weighted average shares, basic253,234230,891194,541188,344166,43313,014·
Weighted average shares, diluted253,234230,891194,541188,344166,43313,014·
Weighted average shares, basic and diluted····166,43313,0144,903
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton SANA · research, not advice